Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACME LaboratoriesDHA:ACMELAB -0.48%85 Debt-to-EBITDA is 3.81 as of Mar. 2026, which is 3% below its 10-year median of 3.91. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT127.25 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 681 Drug Manufacturers companies, ACME Laboratories ranks worse than 77.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for ACME Laboratories's Debt-to-EBITDA or its related term are showing as below:
DHA:ACMELAB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.21 Med: 3.91 Max: 4.54
Current: 4.27
During the past 9 years, the highest Debt-to-EBITDA Ratio of ACME Laboratories was 4.54. The lowest was 3.21. And the median was 3.91.
DHA:ACMELAB's Debt-to-EBITDA is ranked worse than 77.39% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs DHA:ACMELAB: 4.27
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
ACME Laboratories Debt-to-EBITDA Related Terms
ACME Laboratories Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
ACME Laboratories (DHA:ACMELAB) has a Debt-to-EBITDA of 3.81 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ACME Laboratories. This is near median its historical median of 3.91. Over the past decade, ACME Laboratories' Debt-to-EBITDA has ranged from 3.21 to 4.54. According to the industry distribution chart, ACME Laboratories ranks #527 out of 681 companies in the Drug Manufacturers industry, placing it in the top 77.4%.
Is ACME Laboratories' Debt-to-EBITDA too high?
ACME Laboratories' current Debt-to-EBITDA of 3.81 is near median its 10-year median of 3.91. Over the past 10 years, this metric has ranged from a low of 3.21 to a high of 4.54. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. ACME Laboratories' value of 3.81 is 133.7% above this industry median. Based on the distribution chart, ACME Laboratories ranks #527 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #527 out of 681 companies for Debt-to-EBITDA. This places ACME Laboratories in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. ACME Laboratories' value of 3.81 is 133.7% above this benchmark. Historically, ACME Laboratories' own Debt-to-EBITDA has ranged from 3.21 to 4.54 over the past decade. While the company's 10-year median is 3.91 vs. the industry median of 1.63, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Debt-to-EBITDA of 3.81 is 133.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ACME Laboratories. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Debt-to-EBITDA is 3.81, which is near median its own 10-year median of 3.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT127.25, compared to a current price of BDT83.10 — trading 34.7% below its estimated fair value. The current Debt-to-EBITDA is 3.81, which is near median its 10-year median of 3.91 and 133.7% above the Drug Manufacturers industry median of 1.63. ACME Laboratories' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Debt-to-EBITDA is 3.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT83.10 is trading 34.7% below its estimated GF Value™ of BDT127.25.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Debt-to-EBITDA: 3.81 (near median its 10-year median of 3.91)
GF Value™: BDT127.25 vs. price of BDT83.10 (34.7% below fair value)
Industry Position: 133.7% above the Drug Manufacturers median (#527 of 681)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score
Get the complete analysis for DHA:ACMELAB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
